US Patent 9545435 Treatment of short bowel syndrome patients with colon-in-continuity

Patent 9545435 was granted and assigned to Nps Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Nps Pharmaceuticals

Current Assignee

Nps Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9545435

Date of Patent

January 17, 2017

Patent Application Number

15285852

Date Filed

October 5, 2016

Patent Primary Examiner

‌

Satyanarayana R Gudibande

Patent abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9545435 Treatment of short bowel syndrome patients with colon-in-continuity

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API